Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CAR-T immunotherapies may have a new player

29.06.2018

Study finds that natural killer cells engineered with chimeric antigen receptors are equally effective and bring different advantages with less toxicity

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells. In a new study, published June 28 online in Cell Stem Cell, researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also displayed heightened activity against a mouse model of ovarian cancer.


Natural killer cells are immune cells that eliminate infected, foreign and cancer cells.

Credit: NIAID

The findings are significant, say researchers, because NK cells may offer distinct advantages over T-cells, including the ability to safely deliver engineered NK cells in an off-the-shelf manner without patient matching.

"One of the main challenges of immunotherapy has been the clinical manufacture of modified cells," said senior author Dan Kaufman, MD, PhD, professor of medicine in the Division of Regenerative Medicine and director of cell therapy at UC San Diego School of Medicine. "We've shown that you can engineer iPSCs, create chimeric antigen receptor-expressing NK cells to better target refractory cancers that have resisted other treatments."

CAR-T cell-based immunotherapies have garnered considerable attention and investment in recent years. T-cells, a type of white blood cell, are extracted from a patient's blood, genetically modified with a chimeric antigen receptor (the CAR) to bind with a certain protein on the patient's cancer cells, grown in large numbers in a laboratory and then infused into the patient.

"NK cells offer significant advantages as they don't have to be matched to a specific patient," said Kaufman. "Additionally, one batch of iPSC-derived NK cells can be potentially used to treat thousands of patients, which means we can develop standardized, 'off-the-shelf' treatments and use these in combination with other cancer drugs."

Early testing of CAR-T therapies have shown promise -- and sometimes dramatic success -- but there are distinct limitations. First, cells must be isolated from each individual -- a process that takes significant time and money. Additionally, since T-cell therapy is designed to work only for that patient, some patients may not be able to have T cells collected, or they may not have time for this process before the tumor progresses. This means some patients who could potentially benefit will not be able to get CAR-T cell-based therapies.

Moreover, Kaufman noted CAR-T therapies have been associated with sometimes severe toxicities or adverse effects, including unexpected organ damage and death. Previous research by Kaufman and others suggest NK cells do not trigger similar toxicities -- and the latest paper found few adverse effects in mouse models.

"NK cells may just be safer to use," Kaufman said. Kaufman is now collaborating with scientists from San Diego-based Fate Therapeutics to scale up processes to progress to clinical trials.

In their research, the researchers tested CAR NK cells derived from human iPSCs in an ovarian cancer xenograft mouse model, comparing their anti-tumor activity against other versions of NK cells and CAR-T cells. The former demonstrated similar activity to CAR-T cells, but with less toxicity. Kaufman said data indicated ovarian cancer was a good first target, but that other solid tumors, such as breast cancer, brain tumors, and colon cancers, as well as blood cell cancers such as leukemias are also likely to be suitable targets of iPSC-derived NK cells.

###

Co-authors of the study include: Ye Li, UC San Diego; and David Hermanson and Branden S. Moriarty, University of Minnesota, Minneapolis.

Media Contact

Scott LaFee
slafee@ucsd.edu
858-249-0456

 @UCSanDiego

http://www.ucsd.edu 

Scott LaFee | EurekAlert!

Further reports about: CAR blood cell cancer cells immunotherapies mouse model ovarian ovarian cancer tumors

More articles from Health and Medicine:

nachricht Study points to new drug target in fight against cancer
19.09.2019 | Rice University

nachricht Researchers develop tumour growth roadmap
19.09.2019 | Universität Leipzig

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 'Nanochains' could increase battery capacity, cut charging time

How long the battery of your phone or computer lasts depends on how many lithium ions can be stored in the battery's negative electrode material. If the battery runs out of these ions, it can't generate an electrical current to run a device and ultimately fails.

Materials with a higher lithium ion storage capacity are either too heavy or the wrong shape to replace graphite, the electrode material currently used in...

Im Focus: Stevens team closes in on 'holy grail' of room temperature quantum computing chips

Photons interact on chip-based system with unprecedented efficiency

To process information, photons must interact. However, these tiny packets of light want nothing to do with each other, each passing by without altering the...

Im Focus: Happy hour for time-resolved crystallography

Researchers from the Department of Atomically Resolved Dynamics of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg, the University of Hamburg and the European Molecular Biology Laboratory (EMBL) outstation in the city have developed a new method to watch biomolecules at work. This method dramatically simplifies starting enzymatic reactions by mixing a cocktail of small amounts of liquids with protein crystals. Determination of the protein structures at different times after mixing can be assembled into a time-lapse sequence that shows the molecular foundations of biology.

The functions of biomolecules are determined by their motions and structural changes. Yet it is a formidable challenge to understand these dynamic motions.

Im Focus: Modular OLED light strips

At the International Symposium on Automotive Lighting 2019 (ISAL) in Darmstadt from September 23 to 25, 2019, the Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, a provider of research and development services in the field of organic electronics, will present OLED light strips of any length with additional functionalities for the first time at booth no. 37.

Almost everyone is familiar with light strips for interior design. LED strips are available by the metre in DIY stores around the corner and are just as often...

Im Focus: Tomorrow´s coolants of choice

Scientists assess the potential of magnetic-cooling materials

Later during this century, around 2060, a paradigm shift in global energy consumption is expected: we will spend more energy for cooling than for heating....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Technologies: International Symposium „Future Optics“ in Hannover

19.09.2019 | Event News

Society 5.0: putting humans at the heart of digitalisation

10.09.2019 | Event News

Interspeech 2019 conference: Alexa and Siri in Graz

04.09.2019 | Event News

 
Latest News

Quality control in immune communication: Chaperones detect immature signaling molecules in the immune system

20.09.2019 | Life Sciences

Moderately Common Plants Show Highest Relative Losses

20.09.2019 | Life Sciences

The Fluid Fingerprint of Hurricanes

20.09.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>